A B S T R A C r Suppression of pancreatic glucagon secretion by hyperglycemia is a characteristic of normal alpha cell function. However, in diabetic subjects, plasma glucagon is normal or high despite hyperglycemia. It seemed possible that the presence of glucose or its metabolites within the alpha cell might be essential for suppression of glucagon secretion, and that in diabetes an intracellular deficiency of glucose secondary to insulin lack might be responsible for the nonsuppressibility.
A B S T R A C r Suppression of pancreatic glucagon secretion by hyperglycemia is a characteristic of normal alpha cell function. However, in diabetic subjects, plasma glucagon is normal or high despite hyperglycemia. It seemed possible that the presence of glucose or its metabolites within the alpha cell might be essential for suppression of glucagon secretion, and that in diabetes an intracellular deficiency of glucose secondary to insulin lack might be responsible for the nonsuppressibility.
The present study was designed to determine the effect upon glucagon secretion of blockade of glucose metabolism and of experimental insulin deficiency.
Blockade of glucose metabolism was induced in dogs by administration of 2-deoxyglucose or mannoheptulose. A striking rise in glucagon was observed despite accompanying hyperglycemia and hyperinsulinemia, which, in the case of mannoheptulose, was induced by infusing crystalline insulin.
To determine if insulin lack also causes paradoxical hyperglucagonemia, dogs were made severely diabetic by alloxan. Fasting glucagon levels ranged from 3 to 22 times normal despite severe hyperglycemia, and were quickly restored to normal by infusing insulin. Diabetes induced in rats by anti-insulin serum was also associated with significant elevation in plasma glucagon. However, diazoxide-induced insulin lack did not increase glucagon in dogs.
It is concluded that normal suppression of glucagon secretion by hyperglycemia does not occur when glucose metabolism is blocked or when severe insulin deficiency is produced. It is suggested that normal glucose metabolism within the alpha cell may be an insulin-requiring process without which hyperglycemic suppression of glucagon release cannot occur.
INTRODUCTION
Recent studies from this laboratory suggest that in patients with diabetes mellitus the plasma level of pancreatic glucagon is always high, at least in a relative sense (1, 2) . In fasting diabetics, for example, the plasma glucagon concentration is as high as in nondiabetics, despite a level of hyperglycemia, which, if simulated in nondiabetics by means of glucose infusion would suppress glucagon to minimal levels (1). After meals, the glucagon levels of diabetics are also high in relation to the prevailing glucose concentration; a carbohydrate meal fails to induce the prompt decline in plasma glucagon which characterizes the normal response (2) . A protein meal induces in diabetics a rise in glucagon as rapid and as brisk as in normoglycemic nondiabetics, despite hyperglycemia, which in nondiabetics would completely abort protein-induced glucagon rise (2) . Finally, patients with severe ketoacidosis and marked hyperglycemia frequently exhibit a striking elevation of plasma glucagon (3, 1) .
The foregoing findings indicate that in diabetic patients glucagon release is not suppressed by hyperglycemia, which in normal subjects is the most powerful physiologic inhibitor of alpha cell activity (4) . The present studies were, therefore, designed in an attempt to gain insight into the mechanism by which this major restraining influence upon glucagon release is rendered ineffective in diabetes.
Because earlier studies had demonstrated that glucagon release was uniformly enhanced by glucose lack, irrespective of cause (4) (5) (6) , it seemed possible that the hyperglucagonemia of diabetes mellitus might be the consequence of a lack of glucose or its metabolites within the alpha cell, as a consequence of the insulin deficiency. Accordingly, studies were undertaken to assess the effect upon alpha cell function, first, of intracellular blockade of glucose metabolism and, second, of experimental insulin deficiency. postoperative day. After each experiment, the dog was sacrificed and the patency of the T-cannula and the vein was determined. Dogs in which the pancreaticoduodenal vein was not patent were excluded from the study.
Alloxan diabetes was induced in some of the dogs 2 days after the surgery. After a 48 hr fast, these animals were intravenously given 75 mg of -alloxan per kg of body weight as a 5%o solution, followed by a high carbohydrate meal.
Studies in rats. Anti-insulin diabetes was induced in fed rats by the technique of Wright (8) . Under pentobarbitol sodium anesthesia (Nembutal, Abbott Laboratories), a polyethylene catheter was inserted into the right jugular vein. 1-ml blood samples were obtained 15 min before and 30, 60, 90, and 120 min after the injection of either guinea pig antiinsulin serum' with a neutralizing capacity of 2.5 U insulin per ml, or nonimmune guinea pig serum.
Analytical methods. Blood specimens were obtained in syringes rinsed with a 10% solution of ethylenediaminetetraacetate (EDTA) and collected in tubes containing 0.1 ml of Trasylol 500 Kallikrein Inactivator Units) per ml blood.
'Anti-insulin serum was kindly supplied by Dr. Peter Wright.
2 Trasylol was purchased from FBA Pharmaceuticals, Inc., New York.
Plasma was separated immediately and stored at -15 to -20'C for up to 12 wk. Glucose concentration was measured by the ferricyanide method of Hoffman (9) using a Technicon AutoAnalyzer. Insulin was measured by the Herbert modification (10) of the radioimmunoassay of Yalow and Berson (11) . Glucagon was assayed by the previously described radioimmunoassay (12) as most recently modified (1). The anti-glucagon serum employed was 30K, which is highly specific for pancreatic glucagon and cross-reacts only very weakly with glucagon-like immunoreactivity of gastrointestinal origin.
RESULTS
Effect of intracellular blockade of glucose metabolism on glucagon secretion 2-Deoxyglucose. 2-Deoxyglucose, a nonmetabolizable analogue of glucose, is phosphorylated competitively with glucose (13) and appears to block glucose metabolism below the level of glucose-6-phosphate by inhibiting the enzyme phosphohexoisomerase (13) . To determine the effect of a blockade of glucose metabolism upon glucagon secretion four dogs were given an intravenous injection of 300 mg of 2-deoxyglucose per kg of body weight, and the concentrations of plasma glucagon, insulin, and glucose were determined. The results are shown in Table I and Fig. 1 .
Plasma glucose rose promptly in all dogs to a peak averaging 200 mg/100 ml (SEM ±14) at 40 min. Insulin also rose in all animals, reaching a peak at 7.5 min which averaged 257 #U/ml (SEM ±60). Glucagon rose in all Table I ).
dogs within 10 min of the injection to a peak averaging 980 pg/ml (SEM ±253), returning to preinjection levels 60-100 min later (Table I) .
These results are compatible with the thesis that intracellular glucose lack, brought about by interference with glucose metabolism, causes increased secretion of glucagon, despite the presence of high levels of extracellular glucose and insulin, although the unexpected hyperinsulinemia weakens this conclusion.
Mannoheptulose. Mannoheptulose is believed to inhibit insulin secretion (14, 15) by blocking glucose phosphorylation within the beta cell (16) , an effect which it presumably exerts on other cells as well. In order to determine if a block of glucose metabolism within the alpha cell at another level would also influence the release of glucagon, 1. Table II) .
was infused for an hour in three dogs (Fig. 2 and Table  II ). As indicated in Table II , insulin fell promptly to near zero values in all three dogs and glucose rose promptly and progressively to a peak of 401 mg/100 ml at the end of the infusion. The mean glucagon level increased from a preinfusion value of 273 pg/ml to a peak of 1153 pg/ml (SEM ±345) 15 min after termination of the infusion and then declined. To determine if insulin lack, rather than a block of glucose metabolism within the alpha cell, was responsible for the increase in glucagon secretion, plasma insulin was restored to 100 AU/ml or above by infusing insulin with the mannoheptulose (Table III) . Glucagon rose at 60 min to 680 pg/ml despite insulin levels of 100 AU/ml or more. This would suggest that a blockade of glucose metabolism within the alpha cell, rather than the lack of insulin, was the cause of the stimulation of glucagon release.
Effect of insulin lack and insulin repletion on glucagon secretion
AUoxan diabetes. To determine the effect of insulin deficiency upon glucagon secretion, moderate to severe alloxan diabetes with fasting plasma glucose levels in excess of 350 mg/100 ml was produced in four dogs.
Despite the hyperglycemia the plasma glucagon was strikingly increased in all, ranging from 1,900 to 14,000 pg/ml, or from about 3 to 22 times normal. Plasma insulin was markedly reduced relative to the hyperglycemia in all but one of the four animals, the one with the lowest glucagon value. The results are recorded in Table  IV .
To determine if insulin repletion would correct the extreme hyperglucagonemia of alloxan diabetes, insulin was infused at a rate of from 0.15 to 1.5 U/kg per min in four dogs for 150 min. Within minutes after the start of the infusion, plasma glucagon fell precipitously towards normal despite a declining plasma glucose concentration, which in a nondiabetic dog would tend to increase glucagon secretion (4) . These findings, which are recorded in Fig. 3 and Table IV , provide clear evidence that glucagon secretion is greatly increased in insulin deficiency induced by alloxan, despite marked hyperglycemia, and is rapidly suppressed by relatively modest quantities of insulin. It would appear from this that the normal responsiveness of the alpha cells to hyperglycemia requires the presence of insulin.
Diazoxide "diabetes." Diazoxide is believed to suppress directly the release of insulin (17), but is not known to block glucose metabolism. To investigate the effect of diazoxide-induced hypoinsulinemia upon glucagon secretion, two dogs received 50 mg and two dogs 100 mg of diazoxide per kg of body weight as a constant infusion for 120 min. Plasma insulin declined Table IV) .
promptly in all four dogs, the mean insulin concentration averaging less than 5 /AU/ml. This was associated with progressive hyperglycemia which averaged more than 300 mg/100 ml at the end of the infusion. Yet, despite the effective suppression of insulin release by the diazoxide, a rise in glucagon concentration was not observed. Anti-insulin diabetes. To determine the effect of neutralization of circulating insulin upon glucagon secretion a group of five rats was given 1 ml of guinea pig anti-insulin serum by intravenous injection. A control group of nine rats was given 1 ml of nonimmune guinea pig antiserum by the same route. The results are shown in Fig. 4 .
The antiserum-treated group developed hyperglycemia, averaging 666 mg/100 ml (SEM +31), which was significantly greater than the glucose response of the control group (P < 0.001). In this group, plasma glucagon rose from a base line average of 112 pg/ml (SEM ±20) to a peak of 256 pg/ml (SEM ±18) at 120 min. Glucagon was mg/100ml Anti-Serum _-. significantly higher than the level of 104 pg/ml (SEM ±21 ) in the control group at this time (P < 0.001 ).
In a group of six other rats the administration of antiinsulin serum induced only a very mild diabetic state with a mean glucose concentration of 131 mg/100 ml (SEM +4); in these rats the maximum mean glucagon level did not differ significantly from the controls.
DISCUSSION
The foregoing results indicate that certain forms of severe experimental insulin deficiency are associated with striking elevations in plasma glucagon despite the coexistence of marked hyperglycemia. This was most dramatically exhibited in severe chronic insulin deficiency induced in dogs by alloxan. The fact that the hyperglucagonemia in such animals was corrected in part with remarkable rapidity by the infusion of insulin, and at plasma insulin concentrations of only 32-85 ;LU/ml, suggests that the "glucose-blindness" of the alpha cell in this form of diabetes, at least, is the consequence of hypoinsulinemia and implies insulin dependence of the alpha cell. The increased levels of glucagon observed during 2-deoxyglucose administration can as evidence that glucose metabolism within the alpha cell is required to suppress glucagon release; if so, one can ascribe the effects of hypoinsulinemia upon glucagon release to insufficient glucose metabolism within the alpha cell, as suggested by Edwards and Taylor (18) . In the case of the more acute forms of insulin deficiency achieved without injury to the beta cells themselves, the effect on glucagon secretion was variable. The administration of diazoxide, which produces hypoinsulinemia by suppressing insulin release (17) , failed to change plasma glucagon. Perhaps the hypoinsulinemia was of insufficient duration to deplete the alpha cells of products of glucose metabolism, or perhaps the accumulation of insulin within the beta cells as a consequence of diminished insulin release was sufficient to provide insulin through direct contact with juxtaposed alpha cells, or possibly the drug itself interferes with glucagon release in this situation. In the case of the high glucagon levels induced by the administration of mannoheptulose, which, like diazoxide, inhibits insulin release, a direct blockade by the septose of glucose phosphorylation (16) within the alpha cell is probably responsible for the rise; the results cannot be ascribed to hypoinsulinemia per se, since the concomitant infusion of insulin did not prevent the rise.
On the other hand, hypoinsulinemia, induced by antiinsulin serum, was associated with a significant increase in glucagon at the end of 2 hr. Conceivably, the rise in glucagon induced by this form of hypoinsulinemia may reflect a relative depletion of insulin within the islets of Langerhans induced by the antiserum, in contrast to a pharmacologic over-abundance of tissue insulin produced by diazoxide (19) .
In any case, the results in the severely alloxan diabetic dogs indicate that when insulin is deficient both in the plasma and within the islets of Langerhans, alpha cell secretion is not suppressed even by extreme hyperglycemia, possibly because glucose penetration into alpha cells is prevented. The stimulatory effect of 2-deoxyglucose infusion on glucagon secretion suggests that a metabolite of glucose is necessary to suppress the release of glucagon, and it is reasonable, therefore, to ascribe the effect of insulin lack to a deficiency of such metabolites within the alpha cell.
It is of parenthetical teleogic interest that an excess of glucose inhibits the secretion of glucagon, a hormone designed to support vital glucose needs in time of deficit of exogenous glucose, and that a deficit of glucose, whether produced by starvation (4), hypoglycemia (5, 6), or diabetes (1, 2), stimulates its secretion. It would seem that in the basal state the alpha cell is "set" to secrete, just as the beta cell is "set" not to secrete, and that an influx of exogenous glucose will, in a sense, provide energy necessary to "turn off" secretion by the alpha cell and "turn on" beta cell secretion, a teleogically satisfying arrangement for the two cells designed, respectively, to mobilize stored fuels and to store ingested fuels.
These findings are in harmony with, but do not prove, the previously proposed hypothesis (1, 2) that the relative hyperglucagonemia which characterizes the diabetic state in man is a consequence of insulin lack. Yet simple insulin lack fails to explain certain of the observations in human diabetes. It fails to explain adequately the marked hyperglucagonemia observed in certain adulttype diabetics, in whom plasma insulin is, in an absolute sense, in the normal or low normal range (1, 2) . Nor does it account satisfactorily for the high insulin requirements of patients with diabetic ketoacidosis and the hours of therapy required to reduce their marked hyperglucagonemia (3, 1), which contrasts so strikingly with the immediate effect of insulin in severe alloxan diabetes. One is tempted to suggest that if insulin lack is, in fact, the cause of diabetic hyperglucagonemia in man, then some hindrance to insulin-alpha cell interaction must also be postulated.
